TTOO News and Press, T2 Biosystems Inc. From 12/08/22

LEXINGTON, Mass., Dec. 08, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the publication of a peer-reviewed article published by Oxford University Press on behalf of the ...

T2 Biosystems, Inc. (TTOO) Q3 2022 Results Conference Call November 10, 2022 4:30 PM ET Company Participants Emma Poalillo - IR, Gilmartin Group John Sperzel - Chairman, CEO John Sprague - CFO Brett Giffin - CCO Conference Call Participants Kyle M...

T2 Biosystems press release ( NASDAQ: TTOO ): Q3 GAAP EPS of -$2.95 misses by $0.90 . Revenue of $3.68M (-50.5% Y/Y) misses by $1.05M . Achieved sepsis and related revenue (non-COVID product revenue) of $2.4 million, representing a record number for a single qu...

LEXINGTON, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced financial results for the third quarter ended September 30, ...

T2 Biosystems ( NASDAQ: TTOO ) is scheduled to announce Q3 earnings results on Thursday, November 10th, after market close. The consensus EPS Estimate is -$2.05 and the consensus Revenue Estimate is $4.73M (-36.3% Y/Y). Over the last 3 months, EPS estimates have seen 1...

LEXINGTON, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to participate in the upcoming Canaccord Genuity MedTech, Diagnostics and Digital He...

LEXINGTON, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that the U.S. Department of Health and Human Services (“HHS”) and the Steven &...

LEXINGTON, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it received written notice from the NASDAQ Stock Market LLC ...

LEXINGTON, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the third quarter 2022 after market close on Thu...

LEXINGTON, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it has initiated studies to expand the number of pathogens detected on the FDA-cleare...